Fig. 10From: Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trialsForest plot of meta-analysis for the comparison of other adverse events between the SGLT-2i and placebo groups. a Fracture adverse outcomes, b amputation adverse outcomes, c volume depletion adverse outcomesBack to article page